PA
CRSP icon

Perceptive Advisors’s CRISPR Therapeutics CRSP Stock Holding History

Perceptive Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-1,341,308
Closed -$112M – 147
2020
Q3 		$112M Buy
+1,341,308
New +$119M 1.64% 18

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Perceptive Advisors's CRSP Position: Q4 2020 in Review

Perceptive Advisors sold out of CRISPR Therapeutics (CRSP) in Q4 2020, closing a stake of 1,341,308 shares — an estimated $112M sold.

Perceptive Advisors first reported a position in CRSP in Q3 2020 and held it in 1 quarter. The position peaked at $112M in Q3 2020. 412 funds tracked by Wall St. Rank hold CRSP as of Q4 2020.

  • Perceptive Advisors reported no remaining CRISPR Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Perceptive Advisors sold 1,341,308 CRISPR Therapeutics shares in Q4 2020, an estimated $112M.
  • Perceptive Advisors first reported a position in CRISPR Therapeutics in Q3 2020 and held it in 1 quarter.
  • Perceptive Advisors's CRISPR Therapeutics position peaked at $112M in Q3 2020.
  • 412 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2020.

Based on Perceptive Advisors's 13F filing for Q4 2020, filed 16 Feb 2021.